Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Vorolanib in Hepatic Impairment
NCT07809802Phase 1Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of vorolanib (3 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Maximum observed plasma concentration at 120 hours, Area under the plasma concentration-time curve from time 0 to the last measurable concentration at 120 hours and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
vorolanib
Beyond the preview
Go deeper on NCT07809802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809802.